Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

The article concludes that understanding the causes of hair loss and using continuous treatments like minoxidil and finasteride can help manage it, despite potential side effects.

Doxazosin may cause breast enlargement and pain in men.

Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.

The document's conclusion cannot be determined without content.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

Some treatments like minoxidil, finasteride, and dutasteride are effective for hair loss, but there's no agreed best treatment.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

BPH treatments can cause sexual side effects affecting quality of life.

5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.

The treatment effectively promoted hair growth with minimal side effects.

The models can help find better inhibitors for conditions like baldness and prostate disorders.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

Dutasteride may reduce insulin sensitivity and increase body fat.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.

There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

Testosterone increases muscle mass regardless of DHT conversion blocking.

5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.

The document concludes that hair loss in women can be treated with topical treatments or hormone therapy depending on the cause.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

The document concluded that FDA-approved treatments like minoxidil and finasteride are effective for hair loss, while the effectiveness of natural remedies and other non-approved treatments is not well-supported by evidence.

Male pattern baldness may be linked to prostate cancer risk.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.

The market for these drugs is expected to grow.